CliffBio
small molecule

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

DOXORUBICIN HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameDOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Active ingredientDOXORUBICIN HYDROCHLORIDE
Strength50MG/25ML (2MG/ML)
Dosage formINJECTABLE, LIPOSOMAL
RouteINJECTION
ModalitySmall molecule
FDA approvalJuly 2024
Marketing statusRX

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.